# Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

> **NCT04581629** · PHASE2 · COMPLETED · sponsor: **Calcilytix Therapeutics, Inc., a BridgeBio company** · enrollment: 13 (actual)

## Conditions studied

- Autosomal Dominant Hypocalcemia (ADH)
- Autosomal Dominant Hypocalcemia Type 1 (ADH1)

## Interventions

- **DRUG:** Encaleret

## Key facts

- **NCT ID:** NCT04581629
- **Lead sponsor:** Calcilytix Therapeutics, Inc., a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-20
- **Primary completion:** 2023-09-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04581629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04581629, "Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04581629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*